Second-line with paclitaxel and carboplatin for recurrent disease following first paclitaxel and platinum compounds in ovarian carcinoma

被引:0
|
作者
Balbi, G [1 ]
Di Prisco, L [1 ]
Musone, R [1 ]
Menditto, A [1 ]
Cassese, E [1 ]
Balbi, C [1 ]
Cardone, A [1 ]
机构
[1] Univ Naples 2, Dept Obstet & Gynecol, Naples, Italy
关键词
ovarian cancer; paclitaxel; carboplatin; chemotherapy;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The combination of paclitaxel and platinum compounds is considered the best first-line regimen for advanced ovarian carcinoma. The purpose of this study was to evaluate a paclitaxel and carboplatin combination in pretreated patients who recurred within 24 months after a complete clinical response with the same regimen used as first-line chemotherapy. Methods: 18 patients were included in this study. Second-line chemotherapy consisted of paclitaxel, 175 mg/m(2) as a 3-hour infusion, and carboplatin AUC 6 every 21 days. Results: Among 15 evaluable patients, eight (53%) complete and five (34%) partial responses were observed, while two (13%) patients had stable disease (SD). The response rate was 67% among patients with measurable disease and 52% for evaluable disease. The median progress ion-free interval after second-line chemotherapy was 8.3 months. The median progress ion-free interval for patients with measurable disease was 8.6 months and for evaluable disease it was 7.9 months. Seven (46%) of 15 patients have developed recurrence after second-line chemotherapy with paclitaxel and carboplatin with a median time to recurrence of 9.8 months. Conclusion: Paclitaxel 175 mg/m(2) and carboplatin AUC 6 as second-line chemotherapy in this sensitive population is effective in terms of response rate and progression-free interval.
引用
收藏
页码:347 / 349
页数:3
相关论文
共 50 条
  • [1] Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma
    Rose, PG
    Fusco, N
    Fluellen, L
    Rodriguez, M
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) : 1494 - 1497
  • [2] Paclitaxel and carboplatin as second-line therapy in women with platinum-sensitive ovarian carcinoma treated with platinum and paclitaxel as first-line therapy
    Eltabbakh, GH
    Yildirim, Z
    Adamowicz, R
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (01): : 46 - 50
  • [3] Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: Application toward a dynamic disease state model of ovarian cancer
    Dizon, DS
    Hensley, ML
    Poynor, EA
    Sabbatini, P
    Aghajanian, C
    Hummer, A
    Venkatraman, E
    Spriggs, DR
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1238 - 1247
  • [4] Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin
    Ueda, Yutaka
    Miyake, Takahito
    Egawa-Takata, Tomomi
    Miyatake, Takashi
    Matsuzaki, Shinya
    Yokoyama, Takuhei
    Yoshino, Kiyoshi
    Fujita, Masami
    Enomoto, Takayuki
    Kimura, Tadashi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (04) : 829 - 835
  • [5] Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin
    Yutaka Ueda
    Takahito Miyake
    Tomomi Egawa-Takata
    Takashi Miyatake
    Shinya Matsuzaki
    Takuhei Yokoyama
    Kiyoshi Yoshino
    Masami Fujita
    Takayuki Enomoto
    Tadashi Kimura
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 829 - 835
  • [6] Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer
    Takahide Arimoto
    Shunsuke Nakagawa
    Katsutoshi Oda
    Kei Kawana
    Toshiharu Yasugi
    Yuji Taketani
    Medical Oncology, 2012, 29 : 1253 - 1254
  • [7] Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer
    Arimoto, Takahide
    Nakagawa, Shunsuke
    Oda, Katsutoshi
    Kawana, Kei
    Yasugi, Toshiharu
    Taketani, Yuji
    MEDICAL ONCOLOGY, 2012, 29 (02) : 1253 - 1254
  • [8] Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer
    Bolis, G
    Parazzini, F
    Scarfone, G
    Villa, A
    Amoroso, M
    Rabaiotti, E
    Polatti, A
    Reina, S
    Pirletti, E
    GYNECOLOGIC ONCOLOGY, 1999, 72 (01) : 60 - 64
  • [9] Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?
    Gronlund, B
    Hogdall, C
    Christensen, IJ
    Engelholm, SA
    Hansen, HH
    GYNECOLOGIC ONCOLOGY, 2004, 94 (02) : 409 - 415
  • [10] Nedaplatin and paclitaxel comparedwith carboplatin and paclitaxel for patients with platinum-sensitive recurrent ovarian cancer
    Ge, L.
    Li, N.
    Wu, L. Y.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 33 - 34